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Abstract: Hereditary angioedema (HAE) resulting from the deficiency of the C1 inhibitor 
protein is a rare disease, characterized by paroxysms of edema formation in the subcutis and in 
the submucosa. Edema can cause obstruction of the upper airway, which may lead to suffocation. 
Prompt elimination of edema is necessary to save patients from this life-threatening condition. 
Essentially, these edematous attacks are related to the activation of the kinin-kallikrein system 
and the consequent release of bradykinin. Ecallantide (known as DX-88 previously), a potent 
and specific inhibitor of plasma kallikrein is an innovative medicinal product. This is the only 
agent approved recently by the FDA for all localizations of edematous HAE attacks. Its advan-
tages include no risk of viral contamination, high selectivity, very rapid onset of action, good 
tolerability, and straightforward subcutaneous administration. Owing to the risk of anaphylaxis, 
ecallantide should be administered by a health care professional. A postmarketing survey to 
improve risk-assessment and risk-minimization has been launched. The results of these studies 
may lead to the approval of ecallantide for self-administration.
Keywords: hereditary angioedema, C1-inhibitor deficiency, treatment, bradykinin, kallikrein 
inhibitor, subcutaneous administration
Introduction to hereditary angioedema – 
epidemiology and management
Angioedema
The term ‘angioedema’ means recurrent episodes of sudden, occasionally painful 
swelling of the subcutis and deeper tissues without accompanying erythema and itch-
ing; it may also evolve in the submucosa of the upper airways or the gastrointestinal 
tract. Its pathomechanism involves the role of vasoactive mediators enhancing the 
permeability of subcutaneous/submucosal capillaries and postcapillary venules – the 
resulting outflow of plasma into the interstitium produces local edema.1 These media-
tors increasing vascular permeability may be released from mastocytes or basophilic 
cells (through IgE-mediated processes or direct cell activation), through activation of 
the kinin system, or through mechanisms not yet clear.2
Hereditary angioedema
Classification and epidemiology
This inherited form of bradykinin-mediated angioedema is an autosomal dominant 
disorder with three distinct types. Hereditary angioedema (HAE-C1-INH) resulting 
from deficiency of the C1 inhibitor is caused by a mutation in the C1 INH gene and Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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is manifested as two phenotypes.3 More than 200 different 
mutations of the C1INH gene have been described to date.4
In type I HAE-C1-INH, the defective gene does not 
produce a protein. Type II is characterized by the production 
of a dysfunctional inhibitor – therefore, the concentration of 
C1-INH protein may be normal or often elevated, but this 
protein lacks function. Type I is more prevalent, occurring 
in approx. 85% of cases and type II is seen in the remaining 
15 per cent. The estimated prevalence of HAE-C1-INH is 
1:10,000 to 1:50,000 according to international data.5 The 
serine protease C1-INH is involved in the regulation of the 
complement, coagulation, fibrinolytic, and kinin plasma cas-
cade systems.6 These systems undergo activation in C1-INH 
deficiency and the vasoactive mediator bradykinin (produced 
from high-molecular-weight kininogen during activation of 
the kallikrein-kinin system) is responsible for the extravasa-
tion of plasma and the occurrence of characteristic disease 
symptoms.7–9 A third type of hereditary angioedema has been 
described recently. In this type (HAEIII-FXII), plasma level 
and functional activity of the C1-INH protein are both normal 
and although missense mutation of the factor XII gene can be 
demonstrated in approximately 30% of cases, the mechanism 
of edema formation is unknown. The clinical manifestations 
of type III HAE are identical to those seen in HAE caused by 
C1-INH deficiency.10 The following discussion and findings 
all pertain to HAE-C1-INH.
Diagnosis
The diagnosis is established through evaluation of family 
history and clinical manifestations, complement testing, and 
genetics analysis.
Family history
In about 75% of HAE cases, carriers of a mutated C1INH 
gene are found among first-degree relatives. Family members 
of the remaining 25% of patients are not afflicted by this 
abnormality and therefore, their disease is probably caused 
by de novo mutations.5
Clinical symptoms
Time of onset, incidence, location and severity of clinical 
manifestations all exhibit inter-individual variation. Attacks 
begin to occur at around entering school age. Half of the 
afflicted patients experience the initial attack during the 
first 10 years, whereas an additional third of patients during 
the second decade of life.11 Certain factors with a possible 
role in inducing attacks can be identified in a proportion 
of patients and edematous episodes (including mechanical 
trauma, menstruation, pregnancy, infections, oral contracep-
tives,   angiotensin-converting enzyme inhibitors).12 Edema 
can develop on the extremities, trunk, genitals, and face, but 
also in the mucosa of the upper airways or of the intestines. 
Cutaneous edema may be accompanied by pain and defor-
mity (Figure 1). Facial edema may cause severe disfiguration 
with consequent limitation of routine activities, whereas 
loss of function from edema of the extremities may interfere 
with work and activities of daily living. The symptoms of 
abdominal attacks include colicky pain, nausea, vomiting, 
and profuse, watery diarrhoea occurring after the resolution 
of the attack. These symptoms can mimic the clinical mani-
festations of the ‘acute abdomen’ and therefore, patients with 
these manifestations frequently undergo unnecessary surgery 
during their abdominal attack.13,14 Upper airway edema (UAE) 
may lead to asphyxia by causing airway obstruction with 30% 
to 50% mortality in undiagnosed or inappropriately managed 
cases, especially those following a fulminant course.15,16
Complement and genetic studies
HAE-C1-INH can be diagnosed with complement testing; 
molecular genetics analysis is helpful in uncertain cases; it 
is an important tool in prenatal diagnostics. Type I HAE-
C1-INH is characterized by lower C4, as well as reduced 
antigenic and functional C1-INH levels. In Type II HAE-C1-
INH, C4 is reduced, and antigenic C1-INH level is high or 
normal, and the functional activity of C1-INH is impaired.17,18 
Early diagnosis and timely introduction of follow-up care are 
indispensable for preserving the patients’ quality of life.
Management
As HAE is a hereditary disorder, gene therapy would be the 
optimal and definite solution; however, it is not yet   available. 
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The guidelines on the management of HAE have been 
developed through international consensus.17,19 The initial 
step of the management of HAE-C1-INH is counseling and 
education, as these enable the patient to avoid potential trig-
gering factors of attacks as much as possible. If, nevertheless, 
edematous attacks recur frequently, prophylaxis should be 
introduced.20
Long-term prophylaxis is implemented by administering 
antifibrinolytics (tranexamic acid, epsilon-aminocaproic 
acid) or attenuated androgens (stanozolol, danazol, oxan-
drolone, methyltestosterone), although their mode of action 
is still not precisely known.21,22 The use of these drugs – and 
of attenuated androgens, in particular – is limited by the risk 
of side effects, like virilization, liver enzyme elevation, liver 
tumors and dyslipidemia.23 A proportion of the latter can be 
avoided at least partially by administering the lowest effective 
dose, and by their timely recognition as afforded by periodic 
laboratory screens (complete blood count, liver enzyme activ-
ity, creatine kinase, urinalysis) and abdominal ultrasound 
imaging. Drug adverse reactions lead to discontinuation of 
treatment in certain cases.24,25 The agents appropriate for 
long-term prophylaxis also include human plasma-derived 
C1-INH concentrate.26,27 A multicenter clinical study was 
conducted only with the nanofiltrated product (Cinryze®, 
Viropharma), which has been approved by the FDA for the 
prevention of edematous attacks in adolescents and adults. 
This drug has been available in the US since 2009.28
Short-term prophylaxis is recommended for patients 
undergoing surgical or diagnostic interventions on the head 
or neck.29 In this case, attenuated androgens or antifibrinolytic 
agents should be administered in higher doses before the 
intervention, as well as for 4 to 5 days thereafter. However, 
the most effective prophylaxis is C1-INH replacement 
with the concentrate administered 1 hour (less than 6 hours) 
before the intervention.17
Nowadays, there are several options available for the 
acute treatment of edematous attacks (Figure 2).30 The larg-
est body of experience exists with human plasma-derived 
C1-INH concentrate.31 Two intravenous products are cur-
rently marketed. One of them is Berinert P® (Berinert® in 
the US) produced by CSL Behring is available in 28 coun-
tries worldwide.32 In the US, it was approved by the FDA 
in 2009 for the treatment of facial and abdominal edema in 
adolescents and adults.33 A prospective study has proven the 
efficacy and safety of C1-INH concentrate in laryngeal HAE 
attacks.34 The other one, Cetor®, manufactured by the Dutch 
not-for-profit Sanquin Blood Supply Foundation, is another 
blood-derived, purified, nanofiltrated C1-INH concentrate 
that has been used for the emergency therapy of HAE since 
more than 30 years. Recombinant C1-INH (obtained from 
the milk of transgenic rabbits) for intravenously use (devel-
oped by Pharming Group NV), was approved by the EMEA 
in 2010 for treatment of all types of HAE attacks in adults. 
It has been launched in some countries by Swedish Orphan 
Biovitrum (SOBI) under the brand name Ruconest®.35,36 
Icatibant, a bradykinin receptor antagonist (a synthetic 
decapeptide, which is a selective and specific antagonist of 
bradykinin B2 receptors) intended for subcutaneous admin-
istration is available in several European countries. Although 
the evaluation of this drug has been initiated by Jerini AG, its 
clinical development was completed, and the product is being 
marketed currently by Shire under the brand name Firazyr®. 
It has been approved by the EMEA for the management of 
acute edematous attacks (regardless of localization) in adults; 
Firazyr® is not approved in the US.37
In 2011, the European Commission approved Firazyr® 
for self-administration by patients who have mastered the 
technique of subcutaneous injection under the supervision 
of a health care professional. Of all the products licensed 
in Europe for the treatment of acute episodes of type I 
and type II HAE, Firazyr® is the first and only treatment 
licensed for self-administration.
Ecallantide (Kalbitor®, known as DX-88 previously) 
is a recombinant kallikrein inhibitor developed by Dyax 
Corporation.38–41 This is the only product approved recently 
by the FDA for all localizations of edematous HAE attacks 
occurring in patients over 16 years of age. This drug has 
been available in clinical practice since 2009 in the US.42 
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Figure 2 Modes of action of agents appropriate for controlling edematous attacks. 
Notes:  Bradykinin  plays  a  major  role  in  the  pathophysiology  of  hereditary 
angioedema. The initial event is autoactivation of coagulation factor XII, which is 
bound to the surface of the endothelial cells lining the vascular lumen. Factor XIIa 
activates prekallikrein and kallikrein is released as a result. Kallikrein is responsible 
for  the  release  of  bradykinin  from  high-molecular-weight  kininogen  (HMwK). 
C1-INH inhibits the activity of factors XIIa and of kallikrein, whereas ecallantide 
inhibits kallikrein. Icatibant binds to bradykinin B2 receptors.Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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When none of these state-of-the-art treatment modalities is 
available, fresh frozen plasma may be administered if clearly 
indicated. However, it should be taken into account that the 
use of solvent/detergent fresh frozen plasma (SDP; preferred 
over FP/FFP to avoid viral transmission) could theoretically 
worsen attacks. This is because it contains proteins that 
mediate edema formation; moreover, its administration 
remains controversial as there are no clinical trials to sup-
port its use.17,43
The following is a summary of results from clinical 
studies evaluating the pharmacology, mode of action, and 
pharmacokinetics of ecallantide.
Introducing ecallantide
Ecallantide (company code DX-88) is a potent, specific 
and reversible plasma kallikrein inhibitor (Ki = 25 pM). 
  Ecallantide was generated via phage display – a technique for 
the rapid identification of target-specific protein binders – and 
a library consisting of rationally designed variants of the 
first Kunitz domain of human tissue factor pathway inhibi-
tor. Ecallantide is a small, 60 amino-acid, 7062 Da protein, 
produced by recombinant technology (expression in the yeast 
Pichia pastoris) and purified by chromatography.44
Action
Angioedema attacks caused by C1-INH deficiency are medi-
ated by the excessive release of vasoactive bradykinin. This 
release is initiated by the uncontrolled activation of factor XII, a 
protein that autoactivates upon exposure to negatively charged 
surfaces. The activation of factor XII yields factor XIIa and 
kallikrein. C1-INH inhibits both proteases. Kallikrein can 
reciprocally activate more FXII and liberate bradykinin. 
The mechanistic trigger for the initial activation of plasma 
kallikrein in vivo is unknown at present, but the result is the 
cleavage of high-molecular-weight kininogen (HMWK) by 
plasma kallikrein with the release of bradykinin. Bradykinin 
acts on the vasculature to increase capillary and endothelial 
permeability, resulting in extravasation of fluid, which pro-
duces the characteristic signs and symptoms of HAE attacks. 
Acting upon upstream elements in the kinin pathway, ecal-
lantide can produce rapid, specific, complete, and reversible 
blockade of plasma kallikrein, thereby reducing the excess 
of endogenous bradykinin.
Chemistry, dosage and administration
Ecallantide is a clear, sterile solution. Each vial con-
tains 10 mg ecallantide as the active substance along 
with   nonpyrogenic inactive ingredients. Ecallantide is 
  preservative-free, with a pH of approximately 7.0; it is 
stored under refrigeration and should be protected from 
light. Its recommended dose is 30 mg (3.0 mL) adminis-
tered subcutaneously in divided, 10 mg doses; injection 
sites should be distant from the location of angioedema. 
A 30 mg dose is supplied as three vials, each containing 
1 mL of 10 mg/mL ecallantide. If an attack persists, an addi-
tional dose of 30 mg may be administered within 24 hours. 
Ecallantide should only be administered by a health care 
professional with appropriate medical resources to manage 
anaphylaxis and hereditary angioedema.45
Pharmacokinetics and metabolism
In the initial Phase I study, subjects received dose-
ranging intravenous (IV) infusions. Peak concentrations 
occurred 2 to 3 hours after subcutaneous (SC) admin-
istration, although absorption was slightly slower in 
heavier patients. Following the administration of a single 
30 mg SC dose of ecallantide to healthy subjects, a mean 
(± standard deviation) maximum plasma concentration of 
586 ± 106 ng/mL was observed approximately 2 to 3 hours 
postdose. The mean area under the concentration-time curve 
was 3017 ± 402 ng h/mL. Following administration, plasma 
concentration declined with a mean elimination half-life of 
2.0 ± 0.5 hours. Plasma clearance was 153 ± 20 mL/minute 
and the volume of distribution was 26.4 ± 7.8 L. In patients 
and in healthy subjects, ecallantide was shown to distribute 
rapidly in the vascular compartment following either IV or 
SC administration. This rapid distribution was consistent 
with the goal of plasma kallikrein inhibition. The popula-
tion pharmacokinetics of ecallantide has been investigated 
in 35 patients with HAE (24 females and 11 males) and 
in 62 healthy subjects, (34 females and 28 males) aged 11 
to 68 years. No difference in pharmacokinetics was noted 
between these two groups. The clearance of ecallantide 
was 7.56 L/hour, with a steady-state volume of distribu-
tion of 15.1 L. Inter-individual variability was 38% for 
clearance. Ecallantide was cleared rapidly, with an effec-
tive half-life of 0.8 to 4.5 hours. Given the short half-life, 
once-daily administration of multiple doses did not result 
in accumulation, and repeated-dose pharmacokinetics 
was similar to that seen after single doses. Age, sex, and 
baseline creatinine clearance of patients had no impact on 
ecallantide pharmacokinetics. No pharmacokinetic data 
are available in patients or individuals with hepatic or 
renal impairment.44Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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Pharmacodynamics
No exposure-response relationships have been established 
between ecallantide and the components of complement 
or kallikrein-kinin pathways. The effect of ecallantide on 
activated partial thromboplastin time (aPTT) was measured 
in view of a potential effect on the intrinsic coagulation 
pathway. Prolongation of aPTT was observed following 
intravenous dosing with KALBITOR® (ecallantide) at doses 
of approximately 20 mg/m2. When 80 mg was administered 
intravenously to healthy subjects, aPTT increased approxi-
mately two-fold over baseline values and returned to normal 
by 4 hours postdose. No significant QT prolongation has 
been observed in patients taking ecallantide. In a random-
ized, placebo-controlled trial (EDEMA4) studying the 30 mg 
subcutaneous dose vs placebo, 12-lead ECG tracings were 
obtained at baseline, as well as 2 hours and 4 hours postdose 
(covering the period to the expected Cmax), and at follow-up 
(day 7). ECGs were evaluated for PR interval, QRS dura-
tion, and QTc interval. Ecallantide had no significant effect 
on QTc interval, heart rate, or any other components of the 
ECG (DX-88 [ecallantide]).
Clinical studies on the efficacy and safety 
of ecallantide
Efficacy
The results of the first placebo-controlled human study of a 
therapeutic intervention to mitigate the symptoms of HAE 
attacks was published in 2007.40 This double-blind, placebo-
controlled, ascending-dose study assessed the efficacy and 
tolerability of ecallantide administered intravenously in 
different doses (5, 10, 20, or 40 mg/m2) to individuals expe-
riencing HAE attacks (N = 49). Ecallantide ameliorated the 
symptoms of HAE attacks in 72.5% (29/40) of the patients 
treated, whereas 25.0% (2/8) of placebo patients reported 
significant improvement of symptoms within 4 hours 
(P = 0.0169). Ecallantide was well-tolerated at all doses.
The safety and efficacy of ecallantide were evaluated in two 
randomized, double-blind, placebo-controlled trials (EDEMA3 
and EDEMA4) in 168 patients with HAE-C1-INH.
In both trials, the effects of ecallantide were appraised 
using the Mean Symptom Complex Severity (MSCS) score 
and the Treatment Outcome Score (TOS). The MSCS 
score is based on patient-assessed symptom severity (on a 
scale ranging from 0 – normal to 3 – severe) measured at 
baseline, 4 hours, and 24 hours. A decrease in MSCS score 
reflects an improvement in symptoms. The TOS is based on 
patient assessment of response characterized by the change 
in symptom severity vs baseline (on a scale ranging from 
100 – significant improvement to −100 – significant wors-
ening) measured at 4 hours and 24 hours. A TOS value .0 
reflects an improvement in symptoms from baseline.
The EDEMA3 trial was a multicenter, random-
ized, double-blind, placebo-controlled Phase III study. 
160 patients were enrolled and 72 patients (aged 10 years 
or older) who had experienced an attack of HAE at any 
anatomical location with at least one moderate or severe 
symptom were randomized. In a 1:1 ratio, they received 
either subcutaneous ecallantide at a dose of 30 mg, or 
placebo (phosphate-buffered saline, pH 7.0) for attacks 
of HAE (36 in the ecallantide group and 36 in the placebo 
group). An open-label dose of 30 mg of subcutaneous 
ecallantide was allowed for cases with severe upper-
airway obstruction. Patients were observed for at least 
4 hours after administration of the study drug. Final 
assessment of symptoms was done at 24 hours. The pri-
mary endpoint was TOS at 4 hours and the key secondary 
efficacy endpoint was the change from baseline in MSCS 
score at 4 hours.
At 4 hours after dosing with the study drug, median 
TOS was 50.0 for the ecallantide-treated group and 0.0 for 
placebo-treated patients. At 4 hours after administration of the 
study-drug, median change in the MSCS score was −1.00 in 
the ecallantide group and −0.50 in the placebo group. Median 
time to significant improvement in overall response was 
165.0 minutes with ecallantide and .240 minutes with 
placebo.
At 24 hours after administration of the study-drug, 
median TOS was 75.0 for the ecallantide group and 0.0 for 
the placebo group. Median change in the MSCS score at 
24 hours was −1.00 with ecallantide and −0.50 with placebo. 
Median time to sustained improvement in overall response 
was 67.0 minutes in the ecallantide group and 165.0 minutes 
in the placebo group.
Compared to placebo, ecallantide significantly reduced 
the outcome score at 4 hours (the primary endpoint), and the 
mean symptom complex severity score at 4 hours, as well 
as both of these at 24 hours. In the placebo group, 36%, 
whereas in the ecallantide group 14% of patients required 
medical intervention within 24 hours to treat persisting 
symptoms.46 The design of the EDEMA4 trial (double-blind, 
placebo-controlled Phase III study evaluating the treatment of 
patients with a moderate-to-severe HAE attack) was similar 
to that of EDEMA3. Patients were randomized 1:1 to receive 
30 mg of subcutaneous ecallantide or placebo. Ninety-six Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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patients were enrolled. TOS 4 hours after dosing was 53.4 
with   ecallantide vs 8.1 with placebo. Mean (SD) change 
from baseline in MSCS 4 hours after dosing was significantly 
greater with ecallantide (−0.8), than with placebo (−0.4). At 
24 hours, patients treated with ecallantide exhibited a greater 
decrease from baseline in the MSCS score than with placebo 
(−1.5 vs –1.1) and a greater TOS, than with placebo (89 vs 
55). More patients in the placebo group than in the group 
receiving ecallantide required medical intervention to treat 
unresolved symptoms within 24 hours (50% vs 33%).
In the EDEMA4 trial, patients treated with a single 
subcutaneous dose of ecallantide showed a greater decrease 
of MSCS vs baseline and a greater TOS than that seen 
in placebo-treated patients; the differences were statisti-
cally significant.47,48 Riedl et al evaluated the promptness 
of the effect of ecallantide vs placebo using pooled data 
from 143 participants (70 receiving ecallantide and 73 
receiving placebo for 64 abdominal, 55 peripheral and 
24 laryngeal attacks) from two randomized, double-blind, 
placebo-controlled Phase III trials. The quickest onset of 
the therapeutic effect of ecallantide was demonstrated for 
abdominal attacks, followed by laryngeal and peripheral 
attacks.49
Summary of efficacy: Ecallantide was found to be supe-
rior to placebo in relieving symptoms, decreasing the severity 
of attacks, and shortening their duration.
Safety and tolerability
Subcutaneous ecallantide 30 mg was generally well-tolerated 
by patients with attacks of HAE during the EDEMA3 and 
EDEMA4 trials. Most adverse events were mild to mod-
erate in severity, and no event that was more common in 
ecallantide than in placebo recipients occurred in .10% 
of patients.48 Overall, treatment-emergent adverse events 
(TEAEs) occurred at a low rate and were manageable. 
The most common adverse events ($5%) were headache, 
nausea, fatigue, diarrhea, upper respiratory tract infec-
tion, HAE, nasopharyngitis, vomiting, upper abdominal 
pain, and pyrexia; most were mild or moderate in severity. 
Transient, mild, local injection-site reactions were reported 
in a few patients only. The most clinically relevant TEAE 
was hypersensitivity to ecallantide. Overall, 13 patients 
experienced symptoms of possible hypersensitivity dur-
ing the clinical studies. Four of these patients exhibited 
symptoms suggestive of anaphylactoid or anaphylactic 
reactions, such as pruritus, urticaria, allergic rhinitis, 
throat irritation, pharyngeal edema, flushing, wheez-
ing, rhinorrhea, and occasionally hypotension, within 
15 minutes after dosing. These symptoms resolved either 
  spontaneously or   following treatment (eg, with antihista-
mines, epinephrine) in all patients.
Repeated doses of ecallantide were well-tolerated. Of the 
219 patients in the program, 19 (8.7%) received five to nine 
doses and an additional 12 patients (5.5%) received more 
than nine doses of ecallantide.
Patients developed antibodies to ecallantide.   Anti-ecallantide 
antibodies – of all classes and of IgE type against host cell 
proteins (Pichia pastoris) – did not appear to correlate with 
the occurrence of adverse events. Overall, 7.4% of patients 
seroconverted to anti-ecallantide antibodies. The incidence 
of seroconversion seemed to increase with increasing drug 
exposure.46,47
No information is available on drug interactions, as no 
relevant studies have been conducted. Similarly, no clinical 
data exist on the management of pregnant women with HAE. 
The safety and effectiveness of ecallantide in patients under 
16 years of age have not been established. It is not known 
whether ecallantide is excreted in human breast milk. There 
are no animal or human studies to assess the carcinogenic 
or mutagenic potential of ecallantide.
Patients’ perspectives: quality of life, 
patient satisfaction/acceptability, 
adherence and uptake
The management of HAE patients has not changed over 
decades. Appropriate therapies for controlling edematous 
attacks were nonexistent in many countries, including the US. 
In recent years, however, a variety of innovative medicinal 
products have been developed, and their efficacy and safety 
were demonstrated in double-blind, placebo-controlled 
  studies. Simultaneously, these treatment modalities have 
become available for clinical use in an increasing number of 
countries and hence, for an increasing number of patients. 
This is of extreme importance, as the mortality of HAE is 
high even today, owing to delayed diagnosis and lack of 
appropriate therapy, primarily. The range of available thera-
pies expanded on one hand and became extremely variegated 
on the other. Novel agents differ from each other in their 
manufacturing technology, mode of action, and dosage – this 
affords to find the best treatment modality for every patient. 
Individualized patient management is the key to developing 
an optimal and cost-effective therapeutic strategy.50
Helping patients to feel secure is essential. Prerequisites 
to achieving this include awareness of this disorder, making 
an early diagnosis, choosing appropriate treatment, informing 
patients on the nature of HAE, as well as providing regular Clinical, Cosmetic and Investigational Dermatology 2011:4 submit your manuscript | www.dovepress.com
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follow-up care. The feeling of safety is further enhanced 
by having the medication at hand, ready for the emergency 
treatment of edematous attacks anytime and anywhere – this 
is important, as the onset of edema cannot be predicted in 
advance. Long-term prophylaxis cannot eliminate all future 
attacks, including life-threatening edema involving the upper 
airways. Additional problems include undesirable effects and 
insufficient efficacy of prophylactic agents. Prompt manage-
ment of abdominal attacks can help avoiding unnecessary 
  surgery. The optimized management of HAE may reduce the 
cost of care, improve the patients’ quality of life, cut absentee-
ism from school and work, and ease the limitations in activi-
ties of daily living. Ecallantide is a new, effective agent in this 
range of therapies.42 The advantages of ecallantide are that it 
poses no risk of viral contamination; it is highly selective and 
has a quick onset of action. It is also well-tolerated by patients 
and can be administered subcutaneously. Its administration is 
simple, straightforward, and prompt – all these properties are 
important as timely intervention can prevent the escalation of 
the attack. Rapid resolution of edema enables patients to resume 
everyday activities and work as soon as possible. In clinical 
practice, the administration of ecallantide is recommended 
only under the guidance and supervision of a health care pro-
fessional, in facilities where appropriate preconditions exist 
to recognize and manage any potential anaphylactic reaction. 
Dyax proposes implementing a postmarketing risk management 
program (Risk Evaluation and Management Strategy) ensuring 
the safe use of ecallantide to assess frequency and possible 
risk.51 It is hoped that these studies will yield positive results 
and lead to the approval of ecallantide for self-administration 
by patients – this would result in a substantial improvement in 
their quality of life. If ecallantide could be administered anytime 
and anywhere, repeatedly and immediately – ie, without delays 
caused by finding an appropriate health care professional and 
institution – it would significantly improve the patients’ quality 
of life while being cost-effective.
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